The U.S. home infusion therapy market size was estimated at USD 21.95 Billion in 2025 and is expected to reach USD 39.96 billion by 2033, growing at a CAGR of 7.78% from 2025 to 2033. The increasing elderly population susceptible to severe health conditions is a significant factor driving market growth.
In addition, the rising prevalence of disorders such as cancer, diabetes, chronic pain, and gastrointestinal diseases is anticipated to further stimulate growth in the U.S. market. Home infusion therapy provides various advantages for patients, including cost-effectiveness, improved health outcomes, enhanced convenience, and elevated safety standards.
Aging is one of the leading risk factors for developing infections and associated complications. Thus, the rapidly aging U.S. population is anticipated to drive market growth. For instance, according to the Population Reference Bureau, the number of people aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050. Increasing patients’ preference for home therapy is also driving the market growth. Home healthcare supports the daily life activities of patients and provides better access to skilled medical care. As compared to hospital treatment, home infusion therapy is cost-effective since it eliminates hospital stays and ultimately saves the patient’s money. Home infusion therapy also allows the patient to maintain higher safety due to less risk of hospital-acquired infections at home. This augments the demand for home treatment, thereby driving the market growth.
This country’s high prevalence of cancer, diabetes, and other chronic diseases propels market growth further. According to the American Cancer Society, nearly 1.9 million new cancer cases were expected to be diagnosed with 609,360 cancer deaths in 2022. The prevalence of diabetes in the U.S is also quite significant, which can be attributed to negative lifestyle choices and a stressful work environment. Moreover, there has been a constant surge in the prevalence of cardiovascular and chronic respiratory diseases in the country. In addition, factors such as a growing geriatric population and increasing volume of surgical procedures are expected to propel the country’s demand for intravenous infusion pumps in the forecast period.
Moreover, the government is expected to introduce stricter regulations and adopt new standards for safer & efficient practices. This progress is being achieved by improving national standards of care via the Infusion Therapy Standards of Practice and the Policies and Procedures for Infusion Nursing, along with upgrading policies of individual care providers. Moreover, new product launches and FDA approvals significantly contribute to market growth. For instance, in April 2024, Baxter received U.S. FDA clearance for its Novum IQ large volume infusion pump and Dose IQ safety software. This advancement enhances connected and intelligent infusion therapy, improving patient safety and care efficiency.
This product will be delivered within 1-3 business days.
In addition, the rising prevalence of disorders such as cancer, diabetes, chronic pain, and gastrointestinal diseases is anticipated to further stimulate growth in the U.S. market. Home infusion therapy provides various advantages for patients, including cost-effectiveness, improved health outcomes, enhanced convenience, and elevated safety standards.
Aging is one of the leading risk factors for developing infections and associated complications. Thus, the rapidly aging U.S. population is anticipated to drive market growth. For instance, according to the Population Reference Bureau, the number of people aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050. Increasing patients’ preference for home therapy is also driving the market growth. Home healthcare supports the daily life activities of patients and provides better access to skilled medical care. As compared to hospital treatment, home infusion therapy is cost-effective since it eliminates hospital stays and ultimately saves the patient’s money. Home infusion therapy also allows the patient to maintain higher safety due to less risk of hospital-acquired infections at home. This augments the demand for home treatment, thereby driving the market growth.
This country’s high prevalence of cancer, diabetes, and other chronic diseases propels market growth further. According to the American Cancer Society, nearly 1.9 million new cancer cases were expected to be diagnosed with 609,360 cancer deaths in 2022. The prevalence of diabetes in the U.S is also quite significant, which can be attributed to negative lifestyle choices and a stressful work environment. Moreover, there has been a constant surge in the prevalence of cardiovascular and chronic respiratory diseases in the country. In addition, factors such as a growing geriatric population and increasing volume of surgical procedures are expected to propel the country’s demand for intravenous infusion pumps in the forecast period.
Moreover, the government is expected to introduce stricter regulations and adopt new standards for safer & efficient practices. This progress is being achieved by improving national standards of care via the Infusion Therapy Standards of Practice and the Policies and Procedures for Infusion Nursing, along with upgrading policies of individual care providers. Moreover, new product launches and FDA approvals significantly contribute to market growth. For instance, in April 2024, Baxter received U.S. FDA clearance for its Novum IQ large volume infusion pump and Dose IQ safety software. This advancement enhances connected and intelligent infusion therapy, improving patient safety and care efficiency.
U.S. Home Infusion Therapy Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. home infusion therapy market report based on Type, and application.Type Outlook (Revenue, USD Million, 2021-2033)
- Product
- Services
Application Outlook (Revenue, USD Million, 2021-2033)
- Anti-infective
- Endocrinology
- Hydration Therapy
- Chemotherapy
- Enteral Nutrition
- Parenteral Nutrition
- Specialty Pharmaceuticals
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Home Infusion Therapy Market Variables, Trends & Scope
Chapter 4. U.S. Home Infusion Therapy Market: Type Estimates & Trend Analysis
Chapter 5. U.S. Home Infusion Therapy Market: Application Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this U.S. Home Infusion Therapy market report include:- B. Braun Melsungen
- Baxter International,
- Caesarea Medical Electronics Ltd.
- CareFusion
- Fresenius Kabi
- ICU Medical
- JMS CO., LTD.
- Smiths Medical, Inc.
- Terumo Corporation
- Coram LLC
- Option Care Enterprises, Inc.
- BioScrip, Inc.
- BriovaRx Infusion Services
- Paragon Healthcare
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | September 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 21.95 Billion |
| Forecasted Market Value ( USD | $ 39.96 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | United States |
| No. of Companies Mentioned | 15 |
